To observe the effects of Yangxinshi on quality of life，cardiac function and exercise tolerance in patients with chronic heart failure.Methods:A prospective，randomized and controlled clinical study was conducted.Eighty consecutive patients with acute decompensated heart failure who were admitted to Zhongshan Hospital Affiliated to Dalian University from October 2017 to May 2018 and taking a turn for the better 2-4 weeks later were randomly divided into the control group(n＝30)，the Yangxinshi group(n＝30)，the trimetazidine group(n＝10）and the Yangxinshi+ trimetazidine group(n＝10).The observation period was 6 months.All patients were surveyed by cardiopulmonary exercise test，ultrasonic cardiogram at baseline and 6 months after treatment(Clinical Trial Registration Number：NCT03333499).Results:At baseline，there was no significant difference in each observation index between the 4 groups.There was no significant difference in the parameters of exercise test and ultrasonic cardiogram before and after treatment in the control group(P>0.05).The cardiopulmonary exercise test(metabolic equivalent)，ultra echocardiography(left ventricular short axis shortening rate，left ventricular ejection fraction，cardiac output）in the Yangxinshi group，the trimetazidine group and the Yangxinshi+ trimetazidine group were significantly higher than those at baseline and the control group at the same time.Ultrasonic cardiogram(left ventricular end-diastolic volume，left ventricular end-systolic volume）was significantly lower than those before treatment and control group at the same time(P<0.05).The cardiopulmonary exercise test(maximum systolic blood pressure，maximum heart rate and heart rate variability）in the Yangxinshi group and the Yangxinshi group+trimetazidine group were significantly lower than those before treatment and control group at the same time(P<0.05)，while there was no significant difference between the trimetazidine group and before treatment and the control group at the same time(P>0.05).There were no significant differences in cardiopulmonary exercise test，echo cardiograph，between the Yangxinshi group and the Yangxinshi+ trimetazidine group(P>0.05).There were no significant changes in resting systolic pressure，diastolic pressure，pulse pressure difference and resting heart rate among the 4 groups(P>0.05).Conclusion:After 6 months of observation，both Yangxinshi and Trimetazidine can significantly improve cardiac function，reversal myocardial remodeling and improve exercise tolerance in patients with chronic heart failure on the basis of optimizing drug treatment.They have no significant effects on resting blood pressure and heart rate，and Yangxinshi can reduce the maximum systolic pressure，maximum heart rate and heart rate change rate during exercise，as well as make patients more tolerant to exercise state.However，the combination of the 2 drugs has no additional benefits than any single drug.